Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1136.8000 6.50 (0.58%)
NSE Oct 13, 2025 15:31 PM
Volume: 1.5M
 

1136.80
0.58%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 12% YoY to | 3776 crore (I-direct estimate: | 3765 crore) on account of 18% growth in the US to | 1735 crore (I-direct estimate: | 1770 crore). The Europe business grew 6% to | 813 crore (I-direct estimates: | 826 crore) EBITDA margins increased 146 bps YoY to 24.6% (I-direct estimates: 24.0%) mainly on account of an improvement in gross margins. EBITDA grew 19% to | 929 crore (I-direct estimate: | 904 crore)...
Aurobindo Pharma Ltd. is trading below its 200 day SMA of 1143.9
More from Aurobindo Pharma Ltd.
Recommended